Description |
Percentage of patients undergoing diagnostic and therapeutic DAE who experience a significant complication Complication rate (overall, including perforation, bleeding, and pancreatitis) resulting from diagnostic and therapeutic DAE should not exceed 1% and 5%, respectively, in an unselected population |
Domain |
Complications |
Category |
Outcome/Process |
Rationale |
Monitoring for complications is essential to ensure the safety of the procedure |
Construct |
Denominator: Patients undergoing DAE Numerator: Patients in the denominator experiencing a complication (perforation, bleeding, or pancreatitis) Exclusions: None Calculation: Proportion (%) Level of analysis: Service and individual level Frequency: Yearly and/or for a sample of 100 DAEs |
Standards |
Minimum standard: < 5% Target standard: < 5% If the minimum standard is not reached, analysis of the factors influencing complication rate (including assessment of operator numbers, operator experience, case complexity, presence of previous small-bowel surgery, and underlying pathology) should be performed on an individual and service level After evaluation and adjustment, close monitoring should be performed with a further audit within 12 months |
Consensus agreement |
100% |
PICO numbers |
16, 18 (see Supporting information, DAE file) |
Evidence grading |
Moderate-quality evidence |